{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:09:18Z","timestamp":1789153758399,"version":"build-2803163510"},"reference-count":130,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269489","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"36S-44S","source":"Crossref","is-referenced-by-count":0,"title":["Radiopharmaceutical Therapy\u2013Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities"],"prefix":"10.2967","volume":"67","author":[{"given":"Evan R.","family":"Abt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caius G.","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Mona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400904000_67.Supplement_2.36S.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091111400904000_67.Supplement_2.36S.2","doi-asserted-by":"crossref","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci Immunol."},{"key":"2026091111400904000_67.Supplement_2.36S.3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat Commun."},{"key":"2026091111400904000_67.Supplement_2.36S.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2"},{"key":"2026091111400904000_67.Supplement_2.36S.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091111400904000_67.Supplement_2.36S.6","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1038\/s41467-024-55291-x","article-title":"The theranostic genome","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun."},{"key":"2026091111400904000_67.Supplement_2.36S.7","doi-asserted-by":"crossref","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","article-title":"Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases","volume":"15","author":"Mulati","year":"2025","journal-title":"Sci Rep."},{"key":"2026091111400904000_67.Supplement_2.36S.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z"},{"key":"2026091111400904000_67.Supplement_2.36S.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1485"},{"key":"2026091111400904000_67.Supplement_2.36S.10","doi-asserted-by":"crossref","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight."},{"key":"2026091111400904000_67.Supplement_2.36S.11","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.neo.2024.101045","article-title":"Regulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells after treatment with dutasteride and lovastatin","volume":"57","author":"Kuzmanov","year":"2024","journal-title":"Neoplasia."},{"key":"2026091111400904000_67.Supplement_2.36S.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267301"},{"key":"2026091111400904000_67.Supplement_2.36S.13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"L\u00fcckerath","year":"2018","journal-title":"EJNMMI Res."},{"key":"2026091111400904000_67.Supplement_2.36S.14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026091111400904000_67.Supplement_2.36S.15","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1007\/s00259-025-07178-2","article-title":"Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.16","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int J Clin Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/ph16040538","article-title":"Up-regulation of PSMA expression in\u00a0vitro as potential application in prostate cancer therapy","volume":"16","author":"Runge","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026091111400904000_67.Supplement_2.36S.18","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026091111400904000_67.Supplement_2.36S.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262426"},{"key":"2026091111400904000_67.Supplement_2.36S.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268037"},{"key":"2026091111400904000_67.Supplement_2.36S.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110236"},{"key":"2026091111400904000_67.Supplement_2.36S.22","first-page":"55","article-title":"DNA damage repair defects and targeted radionuclide therapies for prostate cancer: does mutation really matter? A systematic review","volume":"13","author":"Filippi","year":"2022","journal-title":"Life (Basel)."},{"key":"2026091111400904000_67.Supplement_2.36S.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.06.053"},{"key":"2026091111400904000_67.Supplement_2.36S.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2068"},{"key":"2026091111400904000_67.Supplement_2.36S.25","unstructured":"Raychaudhuri R Tuchayi AM Low SK . Association of prior PARP inhibitor exposure with clinical outcomes after 177Lu-PSMA-617 in men with castration-resistant prostate cancer and mutations in DNA homologous recombination repair genes. Eur Urol Oncol. February 6, 2025 [Epub ahead of print]."},{"key":"2026091111400904000_67.Supplement_2.36S.26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","article-title":"Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer","volume":"25","author":"Priv\u00e9","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2026091111400904000_67.Supplement_2.36S.27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/RLU.0000000000003541","article-title":"Response to concomitant enzalutamide and 177Lu-PSMA-617 radioligand therapy in ATM-mutated metastatic castration resistant prostate cancer","volume":"46","author":"Satapathy","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2026091111400904000_67.Supplement_2.36S.28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","article-title":"Individual radiosensitivity reflected by \u03b3-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy","volume":"50","author":"Widjaja","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256263"},{"key":"2026091111400904000_67.Supplement_2.36S.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00535-5"},{"key":"2026091111400904000_67.Supplement_2.36S.31","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.3390\/ijms23148037","article-title":"Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment","volume":"23","author":"Ruigrok","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026091111400904000_67.Supplement_2.36S.32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00762"},{"key":"2026091111400904000_67.Supplement_2.36S.33","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-025-00333-y","article-title":"Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model","volume":"10","author":"Vilangattil","year":"2025","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400904000_67.Supplement_2.36S.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.01.001"},{"key":"2026091111400904000_67.Supplement_2.36S.36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-025-07390-0","article-title":"Targeted alpha therapy: a comprehensive analysis of the biological effects from \u201clocal-regional-systemic\u201d dimensions","volume":"53","author":"Song","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265353"},{"key":"2026091111400904000_67.Supplement_2.36S.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265433"},{"key":"2026091111400904000_67.Supplement_2.36S.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.12.002"},{"key":"2026091111400904000_67.Supplement_2.36S.40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/cancers14040953","article-title":"Everything comes with a price: the toxicity profile of DNA-damage response targeting agents","volume":"14","author":"Martorana","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026091111400904000_67.Supplement_2.36S.41","doi-asserted-by":"crossref","first-page":"e390876","DOI":"10.1200\/EDBK_390876","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2026091111400904000_67.Supplement_2.36S.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2026091111400904000_67.Supplement_2.36S.43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"2026091111400904000_67.Supplement_2.36S.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1506-7"},{"key":"2026091111400904000_67.Supplement_2.36S.45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2820"},{"key":"2026091111400904000_67.Supplement_2.36S.46","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.14"},{"key":"2026091111400904000_67.Supplement_2.36S.47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232101"},{"key":"2026091111400904000_67.Supplement_2.36S.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"2026091111400904000_67.Supplement_2.36S.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.07.019"},{"key":"2026091111400904000_67.Supplement_2.36S.50","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat Cancer."},{"key":"2026091111400904000_67.Supplement_2.36S.51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","article-title":"Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity","volume":"1","author":"Carozza","year":"2020","journal-title":"Nat Cancer."},{"key":"2026091111400904000_67.Supplement_2.36S.52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2022.07.014","article-title":"cGAS\/cGAMP\/STING signal propagation in the tumor microenvironment: key role for myeloid cells in antitumor immunity","volume":"174","author":"Mekers","year":"2022","journal-title":"Radiother Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0387"},{"key":"2026091111400904000_67.Supplement_2.36S.54","doi-asserted-by":"crossref","first-page":"29913","DOI":"10.1038\/s41598-024-80677-8","article-title":"A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression","volume":"14","author":"Baird","year":"2024","journal-title":"Sci Rep."},{"key":"2026091111400904000_67.Supplement_2.36S.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313693120"},{"key":"2026091111400904000_67.Supplement_2.36S.56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0932"},{"key":"2026091111400904000_67.Supplement_2.36S.57","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fimmu.2019.00698","article-title":"Targeting the immunomodulatory CD73\/adenosine system to improve the therapeutic gain of radiotherapy","volume":"10","author":"de Leve","year":"2019","journal-title":"Front Immunol."},{"key":"2026091111400904000_67.Supplement_2.36S.58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1544"},{"key":"2026091111400904000_67.Supplement_2.36S.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.03.016"},{"key":"2026091111400904000_67.Supplement_2.36S.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3"},{"key":"2026091111400904000_67.Supplement_2.36S.61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101225"},{"key":"2026091111400904000_67.Supplement_2.36S.62","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0449"},{"key":"2026091111400904000_67.Supplement_2.36S.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.08.024"},{"key":"2026091111400904000_67.Supplement_2.36S.64","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-012-9350-3"},{"key":"2026091111400904000_67.Supplement_2.36S.65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2025.06.3855","article-title":"Evaluating the immune response after targeted radionuclide therapy: toward a correlation between absorbed dose and response","volume":"124","author":"Perrin","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026091111400904000_67.Supplement_2.36S.66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"2026091111400904000_67.Supplement_2.36S.67","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","article-title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","volume":"21","author":"Eapen","year":"2024","journal-title":"Nat Rev Urol."},{"key":"2026091111400904000_67.Supplement_2.36S.68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/cancers17030476","article-title":"Is extraordinary response and long-term remission of metastatic castration-resistant prostate cancer (mCRPC) after [177Lu]Lu-PSMA radioligand therapy due to an immunomodulatory effect (radiovaccination)? A dual center experience on super-responders","volume":"17","author":"Maharaj","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026091111400904000_67.Supplement_2.36S.69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268857"},{"key":"2026091111400904000_67.Supplement_2.36S.70","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.7150\/thno.99516","article-title":"Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics","volume":"14","author":"Hong","year":"2024","journal-title":"Theranostics."},{"key":"2026091111400904000_67.Supplement_2.36S.71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"2026091111400904000_67.Supplement_2.36S.72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3857\/roj.2019.00640","article-title":"The emerging role of myeloid-derived suppressor cells in radiotherapy","volume":"38","author":"Kang","year":"2020","journal-title":"Radiat Oncol J."},{"key":"2026091111400904000_67.Supplement_2.36S.73","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06696-z"},{"key":"2026091111400904000_67.Supplement_2.36S.74","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026091111400904000_67.Supplement_2.36S.75","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s43018-022-00336-7","article-title":"Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization","volume":"3","author":"Nolan","year":"2022","journal-title":"Nat Cancer."},{"key":"2026091111400904000_67.Supplement_2.36S.76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010212"},{"key":"2026091111400904000_67.Supplement_2.36S.77","doi-asserted-by":"crossref","unstructured":"Patel RB Hernandez R Carlson P . Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13:eabb3631.","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"2026091111400904000_67.Supplement_2.36S.78","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.79","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.euo.2020.10.010","article-title":"A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy?","volume":"4","author":"Heidegger","year":"2021","journal-title":"Eur Urol Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.80","doi-asserted-by":"crossref","unstructured":"Kerr CP Jin WJ Liu P . Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition. bioRxiv website. https:\/\/www.biorxiv.org\/content\/10.1101\/2024.12.26.630430v1. Published December 27, 2024. Accessed January 12, 2026.","DOI":"10.1101\/2024.12.26.630430"},{"key":"2026091111400904000_67.Supplement_2.36S.81","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246041"},{"key":"2026091111400904000_67.Supplement_2.36S.82","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.83","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249029"},{"key":"2026091111400904000_67.Supplement_2.36S.84","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/acs.molpharmaceut.2c00281","article-title":"PD-L1-targeted radionuclide therapy combined with \u03b1PD-L1 antibody immunotherapy synergistically improves the antitumor effect","volume":"19","author":"Wen","year":"2022","journal-title":"Mol Pharm."},{"key":"2026091111400904000_67.Supplement_2.36S.85","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","article-title":"Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors","volume":"14","author":"Rudqvist","year":"2023","journal-title":"Nat Commun."},{"key":"2026091111400904000_67.Supplement_2.36S.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2026091111400904000_67.Supplement_2.36S.87","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264373"},{"key":"2026091111400904000_67.Supplement_2.36S.88","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01353-6"},{"key":"2026091111400904000_67.Supplement_2.36S.89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8"},{"key":"2026091111400904000_67.Supplement_2.36S.90","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun."},{"key":"2026091111400904000_67.Supplement_2.36S.91","doi-asserted-by":"crossref","first-page":"e2203410119","DOI":"10.1073\/pnas.2203410119","article-title":"Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation","volume":"119","author":"Mao","year":"2022","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026091111400904000_67.Supplement_2.36S.92","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012599"},{"key":"2026091111400904000_67.Supplement_2.36S.93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0964"},{"key":"2026091111400904000_67.Supplement_2.36S.94","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0984"},{"key":"2026091111400904000_67.Supplement_2.36S.95","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer."},{"key":"2026091111400904000_67.Supplement_2.36S.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.02.024"},{"key":"2026091111400904000_67.Supplement_2.36S.97","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764"},{"key":"2026091111400904000_67.Supplement_2.36S.98","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00259-024-06705-x","article-title":"Targeted interleukin-2 enhances the in\u00a0vivo anti-cancer activity of Pluvicto\u2122","volume":"51","author":"Georgiev","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.036"},{"key":"2026091111400904000_67.Supplement_2.36S.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.029"},{"key":"2026091111400904000_67.Supplement_2.36S.101","doi-asserted-by":"publisher","DOI":"10.15252\/EMBR.202050162"},{"key":"2026091111400904000_67.Supplement_2.36S.102","doi-asserted-by":"crossref","first-page":"965429","DOI":"10.3389\/fmed.2022.965429","article-title":"Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis","volume":"9","author":"Shropshire","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2026091111400904000_67.Supplement_2.36S.103","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/onc.2014.113","article-title":"Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis","volume":"34","author":"Zhou","year":"2015","journal-title":"Oncogene."},{"key":"2026091111400904000_67.Supplement_2.36S.104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-020-04828-5","article-title":"Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy","volume":"48","author":"Khreish","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400904000_67.Supplement_2.36S.105","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-018-0029-9"},{"key":"2026091111400904000_67.Supplement_2.36S.106","doi-asserted-by":"publisher","DOI":"10.1126\/science.ady9543"},{"key":"2026091111400904000_67.Supplement_2.36S.107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47359-5"},{"key":"2026091111400904000_67.Supplement_2.36S.108","doi-asserted-by":"crossref","first-page":"1483769","DOI":"10.3389\/fonc.2025.1483769","article-title":"Landscape of targets within nucleoside metabolism for the modification of immune responses","volume":"15","author":"Dunderdale","year":"2025","journal-title":"Front Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.109","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00721-2"},{"key":"2026091111400904000_67.Supplement_2.36S.110","first-page":"4568","article-title":"Humanized mouse model: a review on preclinical applications for cancer immunotherapy","volume":"10","author":"Yin","year":"2020","journal-title":"Am J Cancer Res."},{"key":"2026091111400904000_67.Supplement_2.36S.111","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1333210"},{"key":"2026091111400904000_67.Supplement_2.36S.112","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.xpro.2021.100574","article-title":"Protocol for tissue slice cultures from human solid tumors to study therapeutic response","volume":"2","author":"Kenerson","year":"2021","journal-title":"STAR Protoc."},{"key":"2026091111400904000_67.Supplement_2.36S.113","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1038\/s41598-024-61684-1","article-title":"Transcriptomic analysis-guided assessment of precision-cut tumor slices (PCTS) as an ex-vivo tool in cancer research","volume":"14","author":"Trivedi","year":"2024","journal-title":"Sci Rep."},{"key":"2026091111400904000_67.Supplement_2.36S.114","doi-asserted-by":"crossref","first-page":"100160","DOI":"10.1016\/j.xcrm.2020.100160","article-title":"Modulation of immune checkpoints by chemotherapy in human colorectal liver metastases","volume":"1","author":"Jabbari","year":"2020","journal-title":"Cell Rep Med."},{"key":"2026091111400904000_67.Supplement_2.36S.115","doi-asserted-by":"crossref","first-page":"e0327322","DOI":"10.1371\/journal.pone.0327322","article-title":"Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells","volume":"20","author":"Durante","year":"2025","journal-title":"PLoS One."},{"key":"2026091111400904000_67.Supplement_2.36S.116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031046"},{"key":"2026091111400904000_67.Supplement_2.36S.117","doi-asserted-by":"crossref","first-page":"17562872241272929","DOI":"10.1177\/17562872241272929","article-title":"PARP inhibitors alone or in combination for prostate cancer","volume":"16","author":"Fenor de la Maza","year":"2024","journal-title":"Ther Adv Urol."},{"key":"2026091111400904000_67.Supplement_2.36S.118","doi-asserted-by":"crossref","first-page":"1073797","DOI":"10.3389\/fmolb.2022.1073797","article-title":"The potential of PARP inhibitors in targeted cancer therapy and immunotherapy","volume":"9","author":"Hunia","year":"2022","journal-title":"Front Mol Biosci."},{"key":"2026091111400904000_67.Supplement_2.36S.119","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s11912-023-01458-6","article-title":"Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer: combination strategies","volume":"25","author":"Arbuznikova","year":"2023","journal-title":"Curr Oncol Rep."},{"key":"2026091111400904000_67.Supplement_2.36S.120","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01060-w"},{"key":"2026091111400904000_67.Supplement_2.36S.121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1681"},{"key":"2026091111400904000_67.Supplement_2.36S.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.024"},{"key":"2026091111400904000_67.Supplement_2.36S.123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210"},{"key":"2026091111400904000_67.Supplement_2.36S.124","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0706-6"},{"key":"2026091111400904000_67.Supplement_2.36S.125","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12528"},{"key":"2026091111400904000_67.Supplement_2.36S.126","doi-asserted-by":"crossref","first-page":"796657","DOI":"10.3389\/fonc.2022.796657","article-title":"Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol."},{"key":"2026091111400904000_67.Supplement_2.36S.127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2268"},{"key":"2026091111400904000_67.Supplement_2.36S.128","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267189"},{"key":"2026091111400904000_67.Supplement_2.36S.129","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00332-8"},{"key":"2026091111400904000_67.Supplement_2.36S.130","doi-asserted-by":"crossref","first-page":"1291253","DOI":"10.3389\/fnume.2023.1291253","article-title":"Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry","volume":"3","author":"Meyer","year":"2023","journal-title":"Front Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:39Z","timestamp":1789152039000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":130,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269489"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269489","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}